WO2010068728A3 - Engineering functional tissue from cultured cells - Google Patents

Engineering functional tissue from cultured cells Download PDF

Info

Publication number
WO2010068728A3
WO2010068728A3 PCT/US2009/067453 US2009067453W WO2010068728A3 WO 2010068728 A3 WO2010068728 A3 WO 2010068728A3 US 2009067453 W US2009067453 W US 2009067453W WO 2010068728 A3 WO2010068728 A3 WO 2010068728A3
Authority
WO
WIPO (PCT)
Prior art keywords
islet
cultured cells
pancreatic islet
cells
hydrogel
Prior art date
Application number
PCT/US2009/067453
Other languages
French (fr)
Other versions
WO2010068728A2 (en
Inventor
Charles A. Vacanti
Original Assignee
The Brigham And Women's Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women's Hospital, Inc. filed Critical The Brigham And Women's Hospital, Inc.
Publication of WO2010068728A2 publication Critical patent/WO2010068728A2/en
Publication of WO2010068728A3 publication Critical patent/WO2010068728A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Described herein is a method for islet cell engineering or regeneration in a subject, wherein a combination of pancreatic islet cells are cultured on a scaffold to form a cell aggregate, and subsequently suspended in a hydrogel and cultured under growth conditions sufficient to form a pancreatic islet. After sufficient growth and/or differentiation of the cells, an engineered islet is isolated from the scaffold and the hydrogel. Engineered islets produced in this manner are functional and can be used as in organ replacement, or augmentation of function. For example, described herein are methods and compositions suitable for producing a functional pancreatic islet for implantation into a subject having Type 1 diabetes.
PCT/US2009/067453 2008-12-11 2009-12-10 Engineering functional tissue from cultured cells WO2010068728A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12183508P 2008-12-11 2008-12-11
US61/121,835 2008-12-11

Publications (2)

Publication Number Publication Date
WO2010068728A2 WO2010068728A2 (en) 2010-06-17
WO2010068728A3 true WO2010068728A3 (en) 2010-11-25

Family

ID=42243307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/067453 WO2010068728A2 (en) 2008-12-11 2009-12-10 Engineering functional tissue from cultured cells

Country Status (1)

Country Link
WO (1) WO2010068728A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011316904B2 (en) 2010-10-22 2016-05-26 Lifeline Scientific, Inc. Cultured pancreas islets
PL2455104T3 (en) 2010-11-19 2013-12-31 Univ Freiburg Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels
KR101798981B1 (en) 2015-09-15 2017-11-17 사회복지법인 삼성생명공익재단 Cell Implant for Islet Grafts and Uses Thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124721A1 (en) * 2001-11-09 2003-07-03 Bentley Cheatham Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
US20040197375A1 (en) * 2003-04-02 2004-10-07 Alireza Rezania Composite scaffolds seeded with mammalian cells
US20080103606A1 (en) * 2006-10-30 2008-05-01 Cory Berkland Templated islet cells and small islet cell clusters for diabetes treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124721A1 (en) * 2001-11-09 2003-07-03 Bentley Cheatham Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
US20040197375A1 (en) * 2003-04-02 2004-10-07 Alireza Rezania Composite scaffolds seeded with mammalian cells
US20080103606A1 (en) * 2006-10-30 2008-05-01 Cory Berkland Templated islet cells and small islet cell clusters for diabetes treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MACROMOL. SYM., vol. 109, 1996, pages 155 - 167 *
THE ANATOMICAL RECORD, vol. 263, 2001, pages 342 - 349 *
TRANSPLANT PROC., vol. 40, no. 5, June 2008 (2008-06-01), pages 1658 - 1663 *

Also Published As

Publication number Publication date
WO2010068728A2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
WO2007002136A3 (en) Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
WO2004029230A3 (en) Cells on a support matrix for tissue repair
MX356756B (en) Pluripotent stem cell culture on micro-carriers.
WO2007051038A3 (en) Pdx1-expressing dorsal and ventral foregut endoderm
WO2008051568A3 (en) Methods and compositions for treatment of bone defects with placental cell populations
WO2010147395A3 (en) Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same
MX2009014273A (en) Methods and compositions for optimized expansion and implantation of mesenchymal stem cells.
WO2007124127A3 (en) Structurally modified acellular tissue engineering scaffolds and methods of production
WO2001023528A8 (en) Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
SG152273A1 (en) Pdx1 expressing endoderm
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
EP1835023A4 (en) Human corneal endothelial cell-derived precursor cell and cell aggregate, process for producing the same, and method for transplanting precursor cell and cell aggregate
MX2009004776A (en) Bone marrow-derived mesenchymal stem cells as a source of neural progenitors.
ATE523592T1 (en) DEHYDRATED CHITOSAN NANOPARTICLES
WO2009133351A3 (en) Production of biofuel from plant tissue culture sources
TW200736399A (en) Expansion and differentiation of neural stem cells under low oxygen conditions
IL203247A (en) Isolated disc stem cells and disc progenitor cells obtained from the nucleus pulposus, methods for producing, methods of using them and compositions comprising same
WO2007143117A3 (en) Differentiation of primate pluripotent cells to hepatocyte-lineage cells
WO2006017176A3 (en) Scaffoldless constructs for tissue engineering of articular cartilage
WO2008086296A3 (en) Acid ceramidase and cell survival
WO2010068728A3 (en) Engineering functional tissue from cultured cells
WO2008008550A3 (en) Compositions and methods for growing human embryonic stem cells
WO2008150001A1 (en) Adipocluster
IL178513A0 (en) Method for the production of a cell composition containing epithelial cells
WO2003069972A3 (en) Hepatocyte precursor cell lines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09832517

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09832517

Country of ref document: EP

Kind code of ref document: A2